Displaying 73 - 84 of 465
Metabolism, Alcohol & Toxicity

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" (Complete Session)

Webcasts
View
Immune-Mediated and Cholestatic Diseases

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" (Complete Session)

Webcasts
View
Metabolism, Alcohol & Toxicity

Discussion and Q&A

Webcasts
View
Metabolism, Alcohol & Toxicity

Introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

NASH: a growing unmet therapeutic need

Webcasts
View
Metabolism, Alcohol & Toxicity

The underestimated role of thyroid hormone pathway in the pathophysiology of NASH

Webcasts
View
Metabolism, Alcohol & Toxicity

Key take home messages and close

Webcasts
View
Metabolism, Alcohol & Toxicity

Welcome and introduction

Webcasts
View
Metabolism, Alcohol & Toxicity

Tools for early detection of metabolic risk in MAFLD

Webcasts
View
Metabolism, Alcohol & Toxicity

Insights from the SIRIUS project – a population-wide liver disease screening program in Slovakia

Webcasts
View
Metabolism, Alcohol & Toxicity

Early screening of metabolic risk – the pharmacists’ perspective

Webcasts
View
Displaying 73 - 84 of 465